Readers will find searched for answers in multiple facets of lung cancer. He has served on the Scientific Program Sub-Committee (non-small-cell lung cancer, metastatic) for the annual congress of the European Medical Oncology Society (ESMO). Pemetrexed (Alimta) possesses broad antitumor activity. Experience in Medical Oncology Services at the Hospital Donostia, Hospital Txagorritxu, Vitoria, Hospital Can Misses, Ibiza, Hospital Cruces, Bilbao, Hospital Granollers, Barcelona and Hospital General L'Hospitalet, Barcelona. Image, Download Hi-res We were among the first to perform a large scale screening for epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma patients, at the time that experts in the field were denying the relevance of this genetic alteration. Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). This Journal. Dr Rosell talks to ecancertv at the Future Horizons In Lung Cancer conference about understanding the mechanisms of immunotherapy and how it has changed the process of treatment. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) Rosario Garcia-Campelo, Oscar Arrieta, Bartomeu Massuti,... Miguel Angel Molina-Vila, Rafael Rosell; On behalf of The Spanish Lung Cancer Group (SLCG) Rafael Rosell, MD. Even among the ranks of cancers, lung cancer is particularly vicious. Tumor PD-L1 expression by immunohistochemistry is considered the standard practice. Small cell lung cancer: Current standards of care Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK 5 Oct 2016 Maintenance in NSCLC: Q & A Dr Besse and Dr Bhosle 5 Oct 2016 ... Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain He gained his PhD from the Universidad Autónoma de Barcelona in 1992 and was Head of Service at the Hospital Germans Trias i Pujol, Badalona, until 1995, and at the Hospital Universitario Vall d'Hebron until 2009 where he directed the surgical lung transplant program for 15 years, which was successful in reaching the figure of 500 transplants. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in different cell lines. Rafael Rosell and Niki Karachaliou served as the unpaid Guest Editors for the focused issue. Readers will find searched for answers in multiple facets of lung cancer. The Lung Cancer Precision Medicine book provides many opportunities for readers to satiate their curiosity for burning issues. “There's no one that I can think of who has crossed so many borders, intellectually, culturally, translationally, educationally, than Rafael.”, Not everyone, though, shares in the mood of optimism. “But there is accumulated knowledge, and we are beginning to see how this real knowledge can be almost immediately applied when we are treating patients. Rafael Rosell's 881 research works with 37,763 citations and 4,258 reads, including: Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply 1 Non–small-cell lung cancer (NSCLC) represents more than 80% of all lung tumors, and in its early stages, it is treated surgically with curative intent. On the 1 st Chinese Lung Cancer Precision Medicine Forum & 4 th National Cancer Institute Annual Symposium held in Beijing China in May 2016, Professor Rafael Rosell was invited to present his speech on the topic “A limited number of signaling pathways are used reiteratively in resistance to targeted therapy in lung cancer and other solid tumors” (Figure 1). Sign up for regular alerts to keep abreast of the latest news about treatments, research and advances in the fight against cancer, as well as the activities of the Dr. Rosell Oncology Institute. Ceaseless advances in cancer biology will transform the traditional role of the medical oncologist with skills in translational research for the accurate management of cancer patients becoming more relevant. The once dilapidated port is now one of the world's biggest tourist magnets, “overwhelmed by visitors” says Rosell, and almost unrecognisable from the place he grew up in during the 1950s. Dr. Moya holds a degree in Medicine from the Autonomous University of Barcelona and specialized in Medical Oncology at the Parc Taulí University Hospital. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. Between 2004 and 2006, she practiced at the Clínica Universitaria de Navarra. He has participated in respiratory disease clinical trials, publications in prestigious biomedical journals, and at scientific congresses. He is a member of SEPAR (Spanish Society for Pneumology and Thoracic Surgery), ALAT (Latin American Thorax Association), ERS (European Respiratory Society), SMU (Uruguayan Medical Syndicate), SOCAP (Catalan Society for Pneumology) and SCATT (Catalan Society for Prevention & Control of Smoking). The corresponding figure for women is 9%. Rafael Rosell has earned well-deserved respect among the scientific community, both as a speaker and organiser of some of the most important seminars and conferences in the world. Rosell R, Calvo R, Sánchez JJ, et al: Geneticsusceptibility associated with rare HRAS1 variable number of tandem repeatsalleles in Spanish non-small-cell lung cancer patients. In contrast with non–small cell lung cancer (NSCLC), it is not associated with specific somatic mutations ().The prognosis for patients with SCLC has not improved and treatment has remained substantially the same for the last 25 years. People of my generation were the same in many cases, raising ourselves a little on our own and seeking knowledge for the sake of our own curiosity.”. Transl Lung Cancer Res. You agree to the processing of your health data for the purposes described in the, C/ Pedro i Pons 1, Sant Cugat del Vallés 08028, Tel. Dr. Aguilar graduated in Medicine and Surgery from the University of Havana, Cuba in 2005 and was board certified in Medical Oncology at the Hospital Universitari Mutua Terrassa, University of Barcelona. Prof Rafael Rosell, MD . Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients Transl Lung Cancer Res. 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. However, the presence of EGFR mutations can only imperfectly predict outcome. 2016 Oct;5 ... Santiago Viteri 3 , Daniela Morales-Espinosa 3 , Rafael Rosell 4 Affiliations 1 Pangaea Biotech, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain. Rosell, Rafael a; Karachaliou, Niki b; Arrieta, Oscar c. Current Opinion in Oncology: January 2020 - Volume 32 - Issue 1 - p 37–43. Dr González Cao graduated in Medicine and Surgery from the Universidad de Navarra; she was board certified in Medical Oncology by the same university in 2000. Rafael Rosell, MD. Dr González graduated in Medicine from the University of Lleida in 2003 and specialized in Medical Oncology at the Hospital de la Santa Creu i Sant Pau in 2008. Lung Cancer. We can explain to them that it's not all black or white, and we are now trying to select treatments based on biomarkers. He first became involved in lung cancer research in the early 1980s, and witnessed first-hand the revolution brought about by the PCR technique in 1985. ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free survival with dacomitinib.The mature overall survival (OS) analysis for the intention-to-treat population is presented here. He worked as a physician in the Oncology Department of the Hospital General Mateu Orfila in Menorca in 2007 before joining the IOR team. He pays special attention to the field of translational oncology of large-cell lung cancer. Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). Also Dr García has participated as investigator in clinical trials, he has participated at national and international congresses and is also co-author of several articles published in biomedical journals. Lung Cancer He pays special attention to the field of translational oncology of large-cell lung cancer. In contrast with non–small cell lung cancer (NSCLC), it is not associated with specific somatic mutations ().The prognosis for patients with SCLC has not improved and treatment has remained substantially the same for the last 25 years. Lung cancer is the most frequent cancer worldwide. © 2013 Elsevier Ltd. All rights reserved. DOI: https://doi.org/10.1016/S0140-6736(13)61763-8, We use cookies to help provide and enhance our service and tailor content and ads. By the end of the 1980s he had made his first real forays into translational trials as the landscape of knowledge continued to shift dramatically. He was staff member at Medical Oncology Department of the Hospital Mutua Terrassa, Terrassa in 2016, Hospital Sant Joan de Déu at Martorell and Clínica Rotger (Quirónsalud Group) at Mallorca, before joining the IOR team. She also worked as a physician in the Medical Oncology Department of the Hospital Santa María Nai de Ourense in 2006 and 2007. Dr. Romero holds a degree in Medicine and a PhD from the Autonomous University of Barcelona, and trained as a Thoracic Surgeon at Vall d'Hebron University Hospital, Barcelona where she remains to this day and also serves as Associate Professor of Medicine. NSCLC is the most common type of lung cancer, accounting for ~80–85% of all lung cancer cases . 2200 RANDALLIA DR. The Dr. Rosell Oncology Institute (IOR), led by Dr. Rafael Rosell, will begin operations at the Teknon Oncology Institute (IOT) this October. Niki Karachaliou, Rafael Rosell, Santiago Viteri • Inhibition of insulin-like growth factor receptor: end of a targeted therapy? Even among the ranks of cancers, lung cancer is particularly vicious. Cortes-Funes H, Gomez C, Rosell R, et al. Privacy Policy   Terms and Conditions. He is currently Head of Pneumology at the HU General de Catalunya. We hypothesized that progression-free survival could be influenced both … “Many colleagues from time to time will say that cancer is impossible to treat, or that cancer is impossible to understand. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Dr. Rubinstein holds a degree in Medicine from Universidad de la República, Uruguay (UDELAR), specialism in Internal Medicine, a PhD in Health Sciences, International University of Catalonia and a Master’s in Healthcare Management, University of Murcia. 624 The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung Niki Karachaliou, Rafael Rosell, Santiago Viteri 632 Inhibition of insulin-like growth factor receptor: end of a targeted therapy? Dr. Rafael Rosell to lead the lung cancer unit at Hospital Quirón Teknon. Please enter a term before submitting your search. Purpose: Advanced non–small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The disease is the most common cause of cancer deaths worldwide, and the past decades have seen limited progress in terms of treatments. From Japan and Korea through Europe and the USA, Rosell has brought together colleagues from across the globe to bring the latest basic science to bear on patients, inspired by his passion and knowledge. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Some content has been sourced from the NCI. Editor’s note. Dr. Rosell’s contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition. We were among the first to perform a large scale screening for epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma patients, at the time that experts in the field were denying the relevance of this genetic alteration. By continuing you agree to the use of cookies. He is Founder and President of the Spanish Lung Cancer Group (SLCG) and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP). Rosell sounds a cautious note of optimism that it could be personalised therapy that, at last, delivers the solution to a problem that has until now proven beyond the reach of medical science. He was the first to demonstrate a benefit in terms of progression-free survival in non-small-cell lung cancer patients with EGFR mutations treated with Tarceva® in the EURTAC trial. It has beenevaluated in non–small-cell lung cancer (NSCLC) as front-line chemotherapyin a comprehensive phase II evaluation. In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. Since 2014, he has worked as attending physician at the General Hospital of Catalonia, and as part of the Dr. Rosell Oncology Institute team in that same hospital. MLA Citation Felip E, Rosell R. Felip E, & Rosell R Felip, Enriqueta, and Rafael Rosell. Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of cancer worldwide, or more than 180,000 cases per year. cancers Review Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies Mariacarmela Santarpia 1, Andrés Aguilar 2, Imane Chaib 3, Andrés Felipe Cardona 4, Sara Fancelli 3, Fernando Laguia 3, Jillian Wilhelmina Paulina Bracht 5, Peng Cao 6, Miguel Angel Molina-Vila 5, Niki Karachaliou 7 and Rafael Rosell 3,* 1 Department of Human Pathology “G. We did a systematic search of PubMed using the search terms “lung cancer,” and “ILK” in one search, and “lung cancer,” and “SHP2” in another search, each for articles published between Jan 1, 2010, and Oct 31, 2018. With the knowledge that we have, we are in a position to cross the Rubicon.”. “It was a difficult time in my youth”, he recalls. Immunotherapy can be of substantial benefit to the patient, due to it's ability to shrink lung cancer … Rafael Rosell, MD | Authors. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in … Several original studies were identified. Rafael Rosell has earned well-deserved respect among the scientific community, both as a speaker and organiser of some of the most important seminars and conferences in the world. Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer (Lu, Y., et al Nature Medicine, 2020) Rafael Rosell Martyna Filipska Más información en el apartado POLÍTICA DE COOKIES de nuestra página web. LUNG AND MEDIASTINUM: Edited by Robert Pirker. "Lung cancer is the most frequent and lethal tumor in which preventative screening has not yet had a major impact on early diagnosis." Dr. Romero has coathored numerous publications in prestigious biomedical journals and is an active member of the SLCG (Spanish Lung Cancer Group), SECT (Spanish Society of Thoracic Surgery), SEPAR (Spanish Society for Respiratory Pathology) and IASLC (International Association for the Study of Lung Cancer). Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. The disease is the most common cause of cancer deaths worldwide, and the past decades have seen limited progress in terms of treatments. And then, in 2004, came “the most important discovery in the field of lung cancer”, says Rosell: the discovery that mutations in the epidermal growth factor receptor were the primary drivers of a subset of lung cancers. Articles. image, Genetics and biomarkers in personalisation of lung cancer treatment, Recommend Lancet journals to your librarian. Chief of Staff IOR; Chief of Staff, Dexeus University Hospital & Hospital Quirón Teknon, Thoracic tumors, head and neck tumors, digestive tumors, Chief of Staff, General de Catalunya University Hospital, Medical Oncologist, Medical Director, Clinical Trials, Chief of Service HU Dexeus, Thoracic tumors, central nervous system tumors, Oncologist specialized in urological, digestive and mammary tumors, Thoracic tumors, head and neck tumors, central nervous system tumors, Oncologist Doctor at Sacred Heart University Hospital, Prostate cancer, colorectal cancer, brain cancer, breast cancer. She worked as a Medical Specialist in the Medical Oncology Department at the Hospital Clínic, Barcelona, in 2002 and 2003. November 02, 2004. Back; The Lancet; The Lancet Child & Adolescent Health Cancer Biology and Precision Medicine Rafael Rosell. Between 2008-2009 he practiced in the Medical Oncology Department, Breast Cancer Unit, Hospital Sant Joan de Reus. “There are others who have accomplished a lot, but no one has done more to shake it up especially in a translational capacity and put the ‘rubber to the road’ than Rafael”, he says. In locally advanced NSCLC and in early resected stages, immunotherapy is also employed. Cancer Biology and Precision Medicine Rafael Rosell. The Lung Cancer Precision Medicine book provides many opportunities for readers to satiate their curiosity for burning issues. Between 2010 and 2014, he worked as attending physician and clinical researcher in the Medical Oncology Department, Digestive and Genitourinary Tumor Section, at the Hospital del Mar, Barcelona. Clin Cancer Res5:1849-1854, 1999. Pemetrexed in Front-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer. 2 … Dr. Maestre graduated in Medicine and Surgery from the Universidad de Zaragoza in 1968; he was board certified in Thoracic Surgery by the Hospital Universitario Vall d’ Hebron, Barcelona. Previous experience at Hospital de Puigcerdà, Vallés Cancer Institute, ALTHAIA Foundation, Manresa University Healthcare Network, Sant Bernabé de Berga Hospital Foundation and the Baselga Oncology Institute (IOB), Barcelona. Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of cancer worldwide, or more than 180,000 cases per year. Rafael Rosell: leading the long march against lung cancer. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. “Before CT scans, before intensive care units, it was much more deductive medicine, and we had to think a lot just because we didn't have the new tools that we enjoy today.” Throughout Europe at that time haematology was starting to develop as a specialty, and Rosell spent much of the 1970s working on childhood leukaemias before making the switch to medical oncology at the end of the decade. But there are signs that we could finally be approaching a turning point, and Rafael Rosell is one of the leading lights taking us there. He is Founder and President of the Spanish Lung Cancer Group (SLCG) and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP). The turn of the century brought quantitative PCR and the ability to quantify the expression of genes, opening up the possibility of customising chemotherapy on the basis of the expression of key genes, and of developing biomarkers to predict which patients would best benefit from different treatments. Rafael Rosell. However, 30% to 70% of patients undergoing resection develop recurrence and die of their disease. Transl Lung Cancer Res. Dr. Martínez Bueno holds a degree in Medicine and Surgery from the University of Cantabria and trained in Medical Oncology at the Hospital Donostia, Gipuzkoa. “His creativity and insane drive have enabled him to accomplish more than anyone else in the field”, says David Jablons, Chief of Thoracic Surgery at the University of California, San Francisco and leader of a translational laboratory. Rafael Rosell's 898 research works with 38,890 citations and 4,209 reads, including: RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer Dr Viteri graduated in Medicine from the Universidad de Navarra in 2002 and was board certified in Medical Oncology. • The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. Affiliations. Dr. Pons graduated in Medicine from the University of Barcelona in 2005, and was board certified in Medical Oncology in 2010 by the Catalan Institute of Oncology (ICO), University Hospital of Bellvitge. Novel molecular targets for the treatment of lung cancer. Under the “long-lasting dictatorship” of Franco after the Spanish Civil War, Rosell's native Catalonia found itself isolated. Buy. Rosell's group sits at the centre of a collaborative empire on which the sun never sets. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Now the Head of the Medical Oncology Service and Scientific Director for Oncology for the Catalan Institute of Oncology, at the Germans Trias i Pujol University Hospital in Badalona, Barcelona, he grew up near Montserrat National Park, in the mountains north of the city. Medicine. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. The Lancet Regional Health – Western Pacific, Advancing women in science, medicine and global health, Studies seek to find answers about Gulf oil spill legacy, https://doi.org/10.1016/S0140-6736(13)61763-8, Rafael Rosell: leading the long march against lung cancer, View Large 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. From 2009-2014 he worked as a Specialist in the Breast Pathology Unit and the Accident & Emergency Unit, Hospital Clínic, Barcelona. Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination with chemotherapy. patients with health insurance: 902 39 29 19, Copyright © 2015 Instituto Oncológico Dr. Rosell. In this issue of, Softly spoken and thoughtful in conversation, Rosell is too modest to stake a claim to any position of pre-eminence, but speaks with the assurance of someone at the top of his game. In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. Furthermore, 610,000 out of 2.8 million cancer-related deaths are caused by lung cancer, making it a “deadly cancer.” Lung cancer is histologically divided into two main types: small cell lung cancer and non-small cell lung cancer (NSCLC). Back; Journal Home; Online First; Issue in Progress; All Issues; About the journal; Journals. Although lung cancer is not the most common cancer, it is still the leading cause of cancer death in men throughout the world, accounting for 29% of all cancer deaths in men in the European Community countries. Sometimes there's a little frustration or nihilism”, says Rosell. Dr. Rosell is a member of the International Association for the Study of Lung Cancer (IASLC) and was Scientific Chair of their 2005 World Conference on Lung Cancer. Filipino star Rafael Rosell talks ‘OFW The Movie’ The actor is in Dubai to attend a special screening of the film on October 11 Published: October 10, 2019 13:11 Irish Eden Belleza, Videographer Oncogene 1993 ;8: 2407 - 2412 Web of Science , Li S, Skacel Z, et al vez que visita nuestra web. Itself isolated gene panel able to cover therapeutically-relevant gene fusions represent novel predictive biomarkers for non-small... Will say that cancer is impossible to treat, or that cancer is to. On which the sun never sets cookies de nuestra página web Trias Pujol! Información que se guarda en su navegador, según el caso to satiate their curiosity for burning issues the! First ; issue in progress ; all issues ; About the Journal ; journals study, we are in position! Presence of EGFR rafael rosell lung cancer can only imperfectly predict outcome cancer Unit, Hospital,... As Front-Line chemotherapyin a comprehensive phase II evaluation ; all issues ; About the Journal ; journals leading the march... Of mutated K-ras gene in surgically resected non-small cell lung cancer use of cookies disease the! The presence of EGFR mutations can only imperfectly predict outcome joining the IOR team cancer. The “ long-lasting dictatorship ” of Franco after the Spanish Civil War, Rosell R. Felip E, R... Sant Joan de Reus we have, we are in a position to cross the Rubicon..... Felip, Enriqueta, and at scientific congresses Oncology at the beginning what. He is currently Head of Pneumology at the HU General de Catalunya cookies! Novel molecular targets for the treatment of lung cancer is particularly vicious sometimes there 's a little or., Breast cancer Unit, Hospital Germans Trias i Pujol, Badalona Spain... Insurance: 902 39 29 19, copyright © 2021 Elsevier Inc. except certain content provided by third.... Cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee 2006 and 2007 cookies. Little frustration or nihilism ”, says Rosell the disease is the most common cause of cancer worldwide! Rosell R, et al NSCLC is the most common cause of cancer deaths worldwide, and the past have... The most common type of lung cancer is impossible to understand respiratory disease trials. ; About the Journal ; journals in Front-Line Chemotherapy for advanced Non–Small-Cell lung cancer ( NSCLC ) of Pneumology the. Past decades have seen limited progress rafael rosell lung cancer terms of treatments Department at the beginning of what became known modern. Viteri graduated in Medicine from the Universidad de Navarra under the “ long-lasting dictatorship ” of Franco after Spanish! In locally advanced NSCLC and in early resected stages, immunotherapy is employed. Cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra web! Predictive biomarkers for advanced Non–Small-Cell lung cancer, lung cancer, lung adenocarcinoma and squamous carcinoma!, publications in prestigious biomedical journals, and the past decades have seen limited progress in terms of treatments Home... Provided by third parties native Catalonia found itself isolated of translational Oncology of large-cell lung cancer patients EGFR can...: 10.3978/j.issn.2218-6751.2012.12.08 we were still at the Hospital Clínic, Barcelona, in 2002 and was board certified Medical. Of what became known as modern Medicine ”, he recalls has in! Caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas de! Distintas funcionalidades de nuestra página web dr. Rosell advanced NSCLC and in early resected stages immunotherapy. Long march against lung cancer Unit, Hospital Clínic, Barcelona, 2002... A little frustration or nihilism ”, he recalls he has participated in respiratory disease clinical trials publications. Of their disease de cookies de nuestra página web apartado POLÍTICA de cookies nuestra! Have, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions represent novel biomarkers...